['pancreatic adenocarcinoma']
['preoperative modified folfirinox and postoperative gemcitabine']

        Inclusion Criteria:

          -  Patients aged 19 years and older

          -  Cytologically or histologically confirmed adenocarcinoma of the pancreas

          -  Met the NCCN criteria for borderline resectable disease (assessed at Aug 23rd, 2015)

          -  No previous chemotherapy or radiotherapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 ~ 1

          -  Adequate bone marrow function as defined by platelets ≥ 100 x 109/L and neutrophils ≥
             1.5 x 109/L

          -  Adequate renal function, with serum creatinine < 1.5 x upper limit of normal (ULN)

          -  Adequate hepatic function with serum total bilirubin < 2 mg/dL, alanine
             aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5 x ULN

          -  No other malignant disease apart from non-melanotic skin cancer or carcinoma in situ
             of the uterine cervix or any other non life-threatening cancer (i.e., prostate or
             thyroid cancer) except where treated with curative intent > 5 years previously without
             evidence of relapse

          -  Written informed consent to the study

        Exclusion Criteria:

          -  No potentially resectable disease or no metastatic disease

          -  Locally advanced unresectable disease according to the NCCN criteria

          -  Histologically confirmed adenosquamous carcinoma

          -  Medical or psychiatric conditions that compromise the patient's ability to give
             informed consent or to complete the protocol or a history of non-compliance

          -  Last dose of radiotherapy received within 4 weeks before the start of study treatment,
             excluding palliative radiotherapy

          -  Obstruction of gastrointestinal tract

          -  Active gastrointestinal bleeding

          -  Myocardial infarction within 6 months prior to the study medication, and other
             clinically significant heart disease (e.g., unstable angina, congestive heart failure
             or uncontrolled hypertension)

          -  Evidence of severe or uncontrolled systemic disease or any concurrent condition which
             in the investigator's opinion makes it undesirable for the patient to participate in
             the study or which would jeopardise compliance with the protocol

          -  Female subjects who are pregnant or lactating, or males and females of reproductive
             potential not willing or not able to employ a highly effective method of birth
             control/contraception to prevent pregnancy from 2 weeks before receiving study drug
             until 3 months after receiving the last dose of study drug. A highly effective method
             of contraception is defined as having a low failure rate (< 1% per year) when used
             consistently and correctly.
      